Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic
DT-001 holds promise to be a game-changing treatment option for a broad range of autoimmune diseases
22-May-2023 -
Dualyx NV, a Ghent based biotech developing next generation immune modulators, announces that it has completed a €40 million ($44 million) Series A financing. The fundraise has been co-led by Fountain Healthcare Partners, Forbion and Andera Partners, with support from existing investors V-Bio ...
antibody development
autoimmune diseases
Series A financing
+1